JP2023089103A5 - - Google Patents

Download PDF

Info

Publication number
JP2023089103A5
JP2023089103A5 JP2023063975A JP2023063975A JP2023089103A5 JP 2023089103 A5 JP2023089103 A5 JP 2023089103A5 JP 2023063975 A JP2023063975 A JP 2023063975A JP 2023063975 A JP2023063975 A JP 2023063975A JP 2023089103 A5 JP2023089103 A5 JP 2023089103A5
Authority
JP
Japan
Prior art keywords
polypeptide
vector
collection
pharmaceutical composition
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023063975A
Other languages
English (en)
Japanese (ja)
Other versions
JP7485422B2 (ja
JP2023089103A (ja
Filing date
Publication date
Priority claimed from JP2020524616A external-priority patent/JP7386537B2/ja
Application filed filed Critical
Publication of JP2023089103A publication Critical patent/JP2023089103A/ja
Publication of JP2023089103A5 publication Critical patent/JP2023089103A5/ja
Application granted granted Critical
Publication of JP7485422B2 publication Critical patent/JP7485422B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023063975A 2017-11-03 2023-04-11 ワクチンt細胞エンハンサー Active JP7485422B2 (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP17200036.6 2017-11-03
EP17200036 2017-11-03
EP17211235.1 2017-12-29
EP17211235 2017-12-29
JP2020524616A JP7386537B2 (ja) 2017-11-03 2018-11-02 ワクチンt細胞エンハンサー
PCT/EP2018/080027 WO2019086615A1 (en) 2017-11-03 2018-11-02 Vaccine t cell enhancer

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020524616A Division JP7386537B2 (ja) 2017-11-03 2018-11-02 ワクチンt細胞エンハンサー

Publications (3)

Publication Number Publication Date
JP2023089103A JP2023089103A (ja) 2023-06-27
JP2023089103A5 true JP2023089103A5 (cg-RX-API-DMAC7.html) 2024-03-05
JP7485422B2 JP7485422B2 (ja) 2024-05-16

Family

ID=64332267

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020524616A Active JP7386537B2 (ja) 2017-11-03 2018-11-02 ワクチンt細胞エンハンサー
JP2023063975A Active JP7485422B2 (ja) 2017-11-03 2023-04-11 ワクチンt細胞エンハンサー

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020524616A Active JP7386537B2 (ja) 2017-11-03 2018-11-02 ワクチンt細胞エンハンサー

Country Status (12)

Country Link
US (1) US11912743B2 (cg-RX-API-DMAC7.html)
EP (1) EP3703744A1 (cg-RX-API-DMAC7.html)
JP (2) JP7386537B2 (cg-RX-API-DMAC7.html)
KR (1) KR102747530B1 (cg-RX-API-DMAC7.html)
CN (1) CN111670046B (cg-RX-API-DMAC7.html)
AU (1) AU2018358019B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020008308A2 (cg-RX-API-DMAC7.html)
CA (1) CA3078692A1 (cg-RX-API-DMAC7.html)
IL (1) IL274409B2 (cg-RX-API-DMAC7.html)
MX (1) MX2020004552A (cg-RX-API-DMAC7.html)
SG (1) SG11202003799RA (cg-RX-API-DMAC7.html)
WO (1) WO2019086615A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12576143B2 (en) * 2018-10-19 2026-03-17 Nouscom Ag Teleost invariant chain cancer vaccine
CN113424264B (zh) * 2018-11-15 2024-04-12 Nouscom股份公司 用于生成个性化癌症疫苗的癌症突变选择
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
EP4061405A1 (en) 2019-11-18 2022-09-28 Janssen Biotech, Inc. Vaccines based on mutant calr and jak2 and their uses
WO2021209897A1 (en) * 2020-04-13 2021-10-21 Janssen Biotech, Inc. Psma and steap1 vaccines and their uses
EP4175664A2 (en) 2020-07-06 2023-05-10 Janssen Biotech, Inc. Prostate neoantigens and their uses
WO2022009049A1 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
AU2022414274A1 (en) * 2021-12-16 2024-08-01 Janssen Biotech, Inc. Prostate cancer vaccines and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4814800B2 (ja) 2004-01-23 2011-11-16 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー チンパンジーアデノウイルスワクチン担体
SI2865387T1 (sl) * 2008-11-21 2019-10-30 Kobenhavns Univ University Of Copenhagen Primiranje imunskega odziva
HUE039908T2 (hu) 2009-02-02 2019-02-28 Glaxosmithkline Biologicals Sa Majom adenovírusból származó nukleinsav- és aminosav-szekvenciák, azt tartalmazó vektorok és alkalmazásuk
NZ616304A (en) 2011-04-08 2016-01-29 Immune Design Corp Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
GB201321384D0 (en) 2013-12-04 2014-01-15 Isis Innovation Molecular adjuvant
EP3190415B1 (en) * 2014-07-25 2019-05-01 Riken Memory invariant nkt cell marker
US20200230220A1 (en) * 2017-07-12 2020-07-23 Nouscom Ag Neoantigen vaccine composition for treatment of cancer

Similar Documents

Publication Publication Date Title
AU723147B2 (en) Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
CN1131712C (zh) 初乳肽及其用途
ES2365077T3 (es) Péptido antígeno anticáncer derivado de sparc y composición farmacéutica que comprende el mismo.
BR0108566A (pt) Método para a regulação negativa in vivo de proteìna amilóide em um animal, incluindo um ser humano e para o tratamento e/ou prevenção e/ou melhora da doença de alzheimer ou outras doenças e condições cartacterizadas por depósitos de amilóide, análogo de um polipeptìdeo amiloidogênico,composição imunogênica, fragmento de ácido nucleico, vetor, célula transformada, composição para induzir a produção de anticorpos contra um polipeptìdeo amiloidogênico, linhagem celular estável, métodos para a preparação de uma célula, para a identificação de um polipeptìdeo amiloidogênico modificado, e para preparação de uma composição imunogênica, uso de um polipeptìdeo amiloidogênico ou de uma subsequência do mesmo, e, uso de um análogo de um polipeptìdeo amiloidogênico
KR20200123696A (ko) 인간 백혈구 항원 a24:02 대립유전자에 특이적으로 결합하는 펩타이드 및 이의 용도
JP2001517957A (ja) ペプチド副甲状腺ホルモン類縁体
HU229282B1 (en) Hiv vaccine compositions
TW200824705A (en) Reconstituted surfactants having improved properties
CN113880915A (zh) 用于修复黏膜损伤或皮肤创伤的多肽及其应用
JP6293882B2 (ja) 遺伝的に安定な腫瘍溶解性rnaウイルス、その製造方法およびその使用
GB1604850A (en) Biologically active peptides
Karpoff et al. Prevention of hepatic tumor metastases in rats with herpes viral vaccines and gamma-interferon.
US20120301495A1 (en) Antigen peptide and use thereof
ES2876036T3 (es) Composición que contiene una bacteria láctica, composición farmacéutica oral para su uso en el tratamiento de infecciones por VPH y/o tumores asociados a VPH y agente inductor de inmunidad de la mucosa para su uso en dotar de inmunidad mucosal contra la infección por VPH
TW434257B (en) Proteins from mammalian liver and their use in oncology
RU2398776C2 (ru) Тимус-специфический белок
ES2390967T3 (es) Epítopo/péptido reconocido por LTC específico para Ep-CAM con restricción por ALH-A2402 y su utilización
CN1251761C (zh) 包含细胞因子诱导的热休克蛋白(hsp)的疫苗
CN107805282A (zh) 一种靶向疗法和免疫疗法联合的多肽
KR20220079081A (ko) 결핵의 예방 또는 치료용 약학적 조성물
CN114478712B (zh) Hpv抗原表位及其鉴定方法、应用
JP6481873B2 (ja) Muc1由来のペプチド、これを用いた癌の治療又は予防のための医薬組成物、免疫誘導剤、及び抗原提示細胞の製造方法
Penn Immunosuppression and cancer: importance in head and neck surgery
WO2015169225A1 (zh) 四分支多肽化合物及其制备方法与应用
Malaguarnera et al. Malignant melanoma of nasal cavity: case report and review of the literature